HONOLULU (Island News) -- Time to look back at seven of the biggest incidents and head-turning moments of 2024. 1. New Year's ...

Geron is also testing the drug for myelofibrosis (MF), another form of bone marrow cancer, and expects data from the phase 3 IMpactMF trial of imetelstat in relapsed/refractory MF in 2024.

We recently compiled a list of the 10 Biggest Losers of This Week. In this article, we are going to take a look at where Geron Corp. (NASDAQ:GERN) stands against the other stocks. Wall Street's ...

In this article, we are going to take a look at where Geron Corp. (NASDAQ:GERN) stands against the other stocks. A wave of selling gripped Wall Street this Friday, pushing major indices lower as ...

H.C. Wainwright has recently initiated Geron Corp (GERN) stock to Buy rating, as announced on November 5, 2024, according to Finviz. Earlier, on October 16, 2024, Scotiabank had initiated the stock to ...

In the preceding three months, 4 analysts have released ratings for Geron GERN, presenting a wide array of perspectives from bullish to bearish. The following table encapsulates their recent ...

Scotiabank analyst Greg Harrison maintained a Buy rating on Geron (GERN – Research Report) today and set a price target of $6.00. The company’s shares closed last Friday at $3.93. Pick the ...

More than 30 years after it was first founded, Geron has claimed FDA approval for its first product – myelodysplastic syndromes (MDS) treatment Rytelo. The US regulator has cleared Rytelo ...